137 related articles for article (PubMed ID: 11896440)
1. Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine.
Carsana M; Tragni G; Nicolini G; Bersani I; Parmiani G; Anichini A; Sun YS; Möller P; Schadendorf D; Sensi ML
Cancer Gene Ther; 2002 Mar; 9(3):243-53. PubMed ID: 11896440
[TBL] [Abstract][Full Text] [Related]
2. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.
Sensi M; Farina C; Maccalli C; Lupetti R; Nicolini G; Anichini A; Parmiani G; Berd D
J Clin Invest; 1997 Feb; 99(4):710-7. PubMed ID: 9045874
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
Sun Y; Jurgovsky K; Möller P; Alijagic S; Dorbic T; Georgieva J; Wittig B; Schadendorf D
Gene Ther; 1998 Apr; 5(4):481-90. PubMed ID: 9614572
[TBL] [Abstract][Full Text] [Related]
5. Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination.
Sensi M; Farina C; Maccalli C; Anichini A; Berd D; Parmiani G
J Immunother; 1998 May; 21(3):198-204. PubMed ID: 9610911
[TBL] [Abstract][Full Text] [Related]
6. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine.
Manne J; Mastrangelo MJ; Sato T; Berd D
J Immunol; 2002 Sep; 169(6):3407-12. PubMed ID: 12218163
[TBL] [Abstract][Full Text] [Related]
7. Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.
Aris M; Bravo AI; Pampena MB; Blanco PA; Carri I; Koile D; Yankilevich P; Levy EM; Barrio MM; Mordoh J
Front Immunol; 2018; 9():955. PubMed ID: 29774030
[TBL] [Abstract][Full Text] [Related]
8. High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition.
Pisarra P; Mortarini R; Salvi S; Anichini A; Parmiani G; Sensi M
Cancer Immunol Immunother; 1999 Apr; 48(1):39-46. PubMed ID: 10235487
[TBL] [Abstract][Full Text] [Related]
9. Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.
Aris M; Bravo AI; Garcia Alvarez HM; Carri I; Podaza E; Blanco PA; Rotondaro C; Bentivegna S; Nielsen M; Barrio MM; Mordoh J
Front Immunol; 2019; 10():2213. PubMed ID: 31620131
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.
Möller P; Sun Y; Dorbic T; Alijagic S; Makki A; Jurgovsky K; Schroff M; Henz BM; Wittig B; Schadendorf D
Br J Cancer; 1998 Jun; 77(11):1907-16. PubMed ID: 9667667
[TBL] [Abstract][Full Text] [Related]
11. Distinct TCRAV and TCRBV repertoire and CDR3 sequence of T lymphocytes clonally expanded in blood and GVHD lesions after human allogeneic bone marrow transplantation.
Hirokawa M; Matsutani T; Saitoh H; Ichikawa Y; Kawabata Y; Horiuchi T; Kitabayashi A; Yoshioka T; Tsuruta Y; Suzuki R; Miura AB; Sawada K
Bone Marrow Transplant; 2002 Dec; 30(12):915-23. PubMed ID: 12476285
[TBL] [Abstract][Full Text] [Related]
12. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
[TBL] [Abstract][Full Text] [Related]
13. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
[TBL] [Abstract][Full Text] [Related]
15. T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines.
Farace F; Angevin E; Poullion I; Leboullaire C; Ferir G; Elias D; Escudier B; Triebel F
Int J Cancer; 1997 Jun; 71(6):972-7. PubMed ID: 9185699
[TBL] [Abstract][Full Text] [Related]
16. [T cell repertoires correlate with pathogenesis of chronic idiopathic thrombocytopenic purpura].
Zhu X; Zhu P; Guo XL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3316-22. PubMed ID: 16409835
[TBL] [Abstract][Full Text] [Related]
17. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.
de Vries IJ; Bernsen MR; Lesterhuis WJ; Scharenborg NM; Strijk SP; Gerritsen MJ; Ruiter DJ; Figdor CG; Punt CJ; Adema GJ
J Clin Oncol; 2005 Aug; 23(24):5779-87. PubMed ID: 16110035
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line.
Osanto S; Schiphorst PP; Weijl NI; Dijkstra N; Van Wees A; Brouwenstein N; Vaessen N; Van Krieken JH; Hermans J; Cleton FJ; Schrier PI
Hum Gene Ther; 2000 Mar; 11(5):739-50. PubMed ID: 10757353
[TBL] [Abstract][Full Text] [Related]
19. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
20. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
